Summary:
Researchers demonstrated that selectively blocking peripheral cannabinoid receptors outside the brain improves memory, synaptic plasticity, and gut barrier integrity in fragile X syndrome mouse models. Tthe study shows that a one-week treatment restores beneficial gut bacteria and reverses hippocampal cognitive deficits without triggering central nervous system side effects.
Key Facts:
- Peripheral Action Without Brain Entry: Unlike conventional cannabinoid-targeting drugs that cross into the central nervous system, the tested compound exclusively inhibits peripheral type 1 cannabinoid (CB1) receptors outside the brain, improving hippocampal memory and synaptic plasticity while avoiding central side effects.
- Repairing the Gut-Brain Axis: Fragile X mice exhibited depleted populations of beneficial Lactobacillus and Akkermansia gut bacteria alongside reduced Muc2 intestinal barrier expression, all of which were restored following the one-week peripheral treatment.
- Therapeutic Path for Intellectual Disability: Because fragile X syndrome is the leading single-gene cause of inherited intellectual disability and autism spectrum disorder, with no approved cognitive treatments, targeting the microbiota-gut-brain axis offers a promising new clinical strategy.
Source: Pompeu Fabra University / Translational Psychiatry
Fragile X syndrome is the most common single-gene cause of inherited intellectual disability and autism spectrum disorder. Alongside cognitive impairment, memory deficits, hyperactivity, and autistic behaviors, individuals living with the condition frequently experience chronic gastrointestinal dysfunction, highlighting the intricate biological link between gut health and neurodevelopment. Despite decades of research, no targeted pharmacological therapies currently exist to treat the cognitive symptoms of fragile X syndrome.
Now, a study led by the Cognition Biology Research Group at Pompeu Fabra University (UPF) in Barcelona and published in Translational Psychiatry reveals that selectively targeting cannabinoid receptors outside the brain can simultaneously heal the gut microenvironment and rescue cognitive function.
Led by principal investigator Dr. Andrés Ozaita alongside co-first authors Lucía de los Reyes Ramírez and Araceli Bergadà-Martínez, the research demonstrates that just one week of peripheral endocannabinoid inhibition reverses synaptic alterations in the hippocampus and restores intestinal barrier integrity in fragile X mouse models.
Treating the Brain by Targeting the Periphery
The endocannabinoid system, particularly type 1 cannabinoid (CB1) receptors, plays a critical role in regulating synaptic transmission, neuroplasticity, and metabolism. Although CB1 receptors are roughly ten times more concentrated in the brain than in peripheral organs, drugs that broadly block central CB1 receptors often carry unacceptable psychiatric and neurological side effects.
To sidestep central nervous system risks, Ozaita and colleagues tested an experimental compound engineered to act strictly on peripheral CB1 receptors without crossing the blood-brain barrier.
“Unlike other drugs that act on the brain, the compound we have tested acts only on peripheral type 1 cannabinoid (CB1) receptors,” explained Ozaita, director of the Cognition Biology Research Group at UPF. “In the same way as in treatments that act on the brain, in mice with the fragile X mutation, this peripheral treatment enhances memory and increases plasticity, which improves the quality of neuronal connections in the hippocampus.”
“Seeing that the results are comparable to those obtained using drugs that act on the whole body, we think that the main effect of broad-spectrum drugs is closely linked to their peripheral action,” Ozaita noted.
Rebuilding Beneficial Gut Bacteria and the Intestinal Barrier
Because neurodevelopmental conditions frequently co-occur with gastrointestinal disturbances, the team examined how peripheral CB1 blockade influenced the gut microbiome and intestinal lining of fragile X mice.
Baseline analysis revealed pronounced gut dysbiosis and mucosal vulnerability in untreated fragile X mice:
- Depleted Beneficial Microbes: Affected mice harbored significantly reduced levels of beneficial gut bacteria belonging to the genera Lactobacillus and Akkermansia.
- Weakened Intestinal Lining: The animals also showed suppressed expression of Muc2, a gene encoding mucin-2, the primary structural protein that maintains the large intestine’s protective physical mucus barrier and regulates immune signaling.
Following the one-week peripheral CB1 inhibitor regimen, both microbial balance and mucosal defenses rebounded.
“Peripheral pharmacological treatment helps restore the microbiome of mutated mice and increases the expression of the Muc2 gene. These two actions improve the ecosystem and the barrier of the large intestine,” said co-first author Lucía de los Reyes Ramírez.
“We cannot state that this recovery of the intestinal environment is due to the specific inhibition of the CB1 receptors in the intestine, but we can say that peripheral inhibition has a positive effect on the microbiota-gut-brain axis in mice carrying the fragile X mutation,” added co-first author Araceli Bergadà-Martínez.
A Safer Blueprint for Human Trials
By showing that cognitive rescue does not require drugs to directly penetrate the brain, and instead can be achieved by modulating the microbiota–gut–brain axis, the findings open a promising translational pathway for fragile X syndrome and related neurodevelopmental disorders.
Future studies will focus on pinpointing the exact signaling messengers linking peripheral CB1 inhibition to hippocampal synaptic remodeling, laying the groundwork for safer, targeted clinical trials in humans.
Questions and Answers
How can a drug that doesn’t enter the brain improve memory in fragile X syndrome?
Researchers at Pompeu Fabra University found that blocking peripheral type 1 cannabinoid (CB1) receptors outside the brain improves gut microbiome health and strengthens the intestinal barrier. These positive changes along the microbiota–gut–brain axis translate into healthier neuronal connections and improved memory in the brain’s hippocampus, without causing psychiatric side effects.
What gut abnormalities were found in fragile X syndrome models?
Mice with the fragile X mutation had lower levels of beneficial gut bacteria (Lactobacillus and Akkermansia) and reduced expression of the Muc2 gene, which produces the protective mucus barrier lining the large intestine.
Why is this discovery important for developing human treatments?
Currently, there is no approved medication to treat intellectual disability or memory impairment in fragile X syndrome, and drugs that block cannabinoid receptors inside the brain often cause adverse neurological side effects. Targeting peripheral receptors outside the brain offers a potentially much safer therapeutic strategy.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuroscience and aging Research:
- Media Contact: Marta Vila Cejudo
- Source: UPF Barcelona
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Translational Psychiatry (Nov 19, 2026). “A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome.” Authors: Lucía de los Reyes-Ramírez, Araceli Bergadà-Martínez, Sara Martínez-Torres, Irene Martínez-Gallego, Pilar Losada-Ruiz, Silvia Arboleya, Antonio González-Matute, Miguel Gueimonde, Rafael Maldonado, Antonio Rodríguez-Moreno & Andrés Ozaita.
- DOI: 10.1038/s41398-026-04360-4
Abstact
A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome
Fragile X syndrome (FXS) is the principal monogenic syndrome leading to inherited intellectual disability and autism. It is caused by the silencing of FMR1 gene that leads to the loss in the expression of its encoded protein, the fragile X messenger ribonucleoprotein 1 (FMRP). In synapses, FMRP has a key role in local mRNA modulation to maintain synaptic plasticity.
The Fmr1 KO (FX) mouse model shows cognitive impairment and some of the synaptic traits present in individuals with FXS, together with alterations in gut microbiota. Previous studies revealed that pharmacological and genetic cannabinoid type-1 receptor (CB1R) inhibition significantly prevented central key alterations in FX mice. Here, we aimed to evaluate the effect of a sub-chronic treatment with the largely peripherally-restricted CB1R antagonist AM6545.
We found that AM6545 reduced memory deficits and restored enhanced hippocampal mGluR5-dependent long-term depression and aberrant dendritic spine density in FX mice. At the peripheral level, AM6545 modified altered FX mice fecal microbiota composition and intestinal Muc2 expression, while in the hippocampus AM6545 treatment upregulated hippocampal Htr4, the gene encoding for serotonin receptor 4 (5-HT4R). This upregulation, also observed in cecum, positively correlated with memory performance. Notably, acute pharmacological blockade of 5-HT4R abolished AM6545 pro-cognitive effect.
Our results suggest that repeated peripheral CB1R inhibition ameliorates key central and peripheral alterations in FXS mouse model and modifies the expression of serotonergic receptors important for cognitive performance. Together, this evidence points to the peripheral targeting of CB1R as an approach to alleviate cognitive dysfunction in the FXS context.

